- This MoU promises to open newer avenues for the Indian life sciences community with the opportunities in the Middle East market through the platform of the DuBiotech free zone.
- The park offers a conducive environment including an innovative academic and commercial infrastructure where Indian pharma companies can greatly benefit from, and contribute to. For example, the Nucleotide Complex in DuBiotech, the laboratory building with facilities enabling companies to conduct laboratory-based research and analysis removes the need for individual companies to build their own dedicated facilities.
- As India has a strong pharma-manufacturing industry particularly known for its generics manufacturing, DuBiotech hopes to see more R&D collaborations between Indian companies and Middle East-based academic and clinical expertise.
- As Indian companies move towards extending their abilities to develop new products, DuBiotech can assist Indian companies to easily access regional networks to connect with institutions and companies with whom they can collaborate for shared benefits
Stay updated on various stakeholders of Healthcare ecosystem
Tuesday, June 12, 2012
DuBiotech to ink pact with IDMA; offers array of incentives for Indian pharma companies
Dubai Biotechnology and Research Park (DuBiotech), one of the top life sciences clusters in the Middle East region embracing the biotechnology, pharmaceutical and medical device, and healthcare technology industries, is soon to enter into a memorandum of understanding (MoU) with the Indian Drug Manufacturers' Association (IDMA).
Subscribe to:
Post Comments (Atom)
Thank you :)
ReplyDelete